GC Genome Corp
340450
Company Profile
Business description
GC Genome Corp is a clinical genome analysis company specializing in clinical genome analysis. It is a precision medicine leader that continuously and actively researches and develops personalized precision medicine technology with the goal of utilizing personal genome data analysis information collected from disease diagnosis and treatment sites for early screening and prediction of diseases, and further customized treatment.
Contact
107, Ihyeon-ro 30beon-gil
Giheung-gu
Gyeonggi-do
Yongin-si16924
KORT: +82 312609600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
125
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks
Going into earnings, Is Meta stock a buy, a sell, or fairly valued?
With a focus on leveraging its AI investments, here’s what we think of Meta stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 15.30 | 0.17% |
| CAC 40 | 7,738.30 | 59.92 | -0.77% |
| DAX 40 | 24,048.74 | 259.06 | -1.07% |
| Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
| FTSE 100 | 8,996.52 | 16.47 | -0.18% |
| HKSE | 25,130.03 | 135.89 | 0.54% |
| NASDAQ | 20,974.18 | 78.52 | 0.38% |
| Nikkei 225 | 39,774.92 | 44.19 | -0.11% |
| NZX 50 Index | 12,833.74 | 127.77 | -0.99% |
| S&P 500 | 6,305.60 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,677.20 | 9.00 | 0.10% |
| SSE Composite Index | 3,581.86 | 22.07 | 0.62% |